SUBJECT INDEX: VOLUME 44 (2004)

In the subject index, the page number refers to the first page of the communication in which the subject is addressed rather than to the specific page on which the referenced key words can be found. An "L" in parentheses following the page number indicates that the subject entry appeared in a letter to the editor; an "E" in parentheses indicates that the subject was discussed in an editorial; a "/" between numbers indicates on what page the correction for the subject entry appears.

In Volume 44 (2004), Number One (January) contains pages 1-144; Number 2 (February), pages 145-310; Number 3 (March), pages 311-466; Number 4 (April), pages 467-626; Number 5 (May), pages 627-800; Number 6 (June), pages 801-954; Number 7 (July), pages 955-1132; Number 8 (August), pages 1133-1270; Number 9 (September), pages 1271-1400; Number 10 (October), pages 1401-1542; Number 11 (November), pages 1543-1678; and Number 12 (December), pages 1679-1816.

A

AABB
- PLT testing standards ... 311(E), 450
- vision statement ... 1402(E)

ABO blood group
- DNA sequence analysis ... 1394(L)
- fluorescence cytometric typing ... 187
- genotyping by minisequencing analysis ... 943(L)
- *O* alleles ... 707
- race/ethnicity and ... 703

ABO gene transcriptional regulation ... 1741

ABO incompatibility
- allo-PBPCT ... 1603
- HSCT, pure red blood cell aplasia from ... 946(L)
- immunohemolytic reaction ... 860
- IUT ... 1357

ACE inhibitors ... 1361

Activation markers ... 49, 125

Acute lung injury, transfusion-related. *See* TRALI

ADAMTS13 deficiency ... 146

Additive solutions ... 977, 990, 1204, 1656

Adhesion molecules, mobilization and ... 1769

Adverse events
- in blood donors ... 135(L)
- cryopreserved BM and PBPC infusion ... 907
- double-filtration plasmapheresis ... 1621
- DVT after blood donation ... 586
- hyperphosphatemia after plasma exchange ... 947(L)
- reporting/investigation of ... 907
- TTP-HUS after allogeneic HPC transplantation ... 294
- WPM ... 973

Aerobic bacteria inactivation ... 1496

Age, donor ... 597, 1640

Alcohol disinfection ... 1238

ALL ... 777

Allergic transfusion reactions ... 16, 25

Alloantibodies ... 5(E), 187, 1273

Allogeneic blood transfusion
- AHIA after ... 5(E), 67
- Fas/FasL expression after ... 158
- IV iron for hip fracture patients ... 1447
- reactions, effect of leukoreduction on ... 25
- relative risk ... 632
- volume ... 632

Alloimmune thrombocytopenia ... 844

Alloimmunization ... 67

Allosensitization, warm autoantibodies and ... 67

ALT elevation, HEV RNA analysis ... 934

American Red Cross
- donor data ... 1640
- WPM data ... 1112

Amicus Crescendo cell separator ... 758

Amino acid residues ... 173

7-Aminoactinomycin D ... 547

AML ... 777

Amostosalen, with UVA light treatment ... 877, 1159, 1496, 1732

Anaerobic bacteria inactivation ... 1496

Anaphylactic transfusion reactions ... 509

Anemia
- acquired aplastic ... 814
- autoimmune hemolytic ... 5(E), 67
- erythropoietin and iron therapy for ... 2S:15
- Hb-based oxygen carriers for ... 1516
- in HIV, HAART era and ... 826
- monitoring during ANH ... 2:S26
- teicoplanin-associated immune hemolytic ... 73

Anesthesia, normovolemic hemodilution and ... 2S:26

Animal models
- Fas/FasL expression after blood transfusion ... 158
- GalT-KO pig RBCs for blood transfusion ... 1004
- hamster window chamber model ... 1626
- Hb-based oxygen carriers ... 1516
- PEN110 inhibition of xenogeneic GVHD ... 282
- PLT immunity in ... 1572
- PLT storage ... 865
- porphyrin photosensitizers ... 1186
- vCJD plasma infectivity, protease treatment and ... 1700
- xenotransplantation ... 555

Annexin V binding ... 716

Anti-A/A,B titers ... 805

Antibiotic-induced immune hemolytic anemia ... 73

Antibodies, drug-dependent ... 1033

Anti-CD62 ... 1487

Anticoagulant therapy ... 229, 605

Anti-D
- affinity ... 399
- carriers ... 1282
- hemolysis, donor lymphocyte-mediated ... 1635
- IgG prophylaxis in D⁻ mothers ... 512
- induced by blood transfusion ... 5(E), 1720
- infant ... 747

Anti-DCF/RBC antibodies ... 1226

Anti-Gal ... 1004

Anti-HBc-reactive donors ... 1332

Anti-HCV ... 343, 1706, 1755

Anti-HCV immunoblot assay ... 349

Anti-HCV immunologic assay ... 59

Antihistamines ... 907

Anti-IgA ... 382

Anti-IgG, oxaliplatin-induced hemolysis and ... 838

Anti-Jk^a ... 1259(L)

Anti-Jr^a ... 197

Anti Kn^a ... 164

Anti-N F(ab) affinity ... 173

Anti-Rh17 ... 1357

Apheresis
- aspirin ingestion before ... 1300
- leukapheresis ... 229, 750, 758, 1104, 1593
- perioperative ... 2S:54
- plasma ... 2S:54, 917, 1621
- therapeutic ... 795(L)
- WPM ... 1112

Apheresis devices ... 119, 125, 1104

Aplastic anemia ... 268, 814

Apoptosis ... 313, 716

Aprotinin ... 2S:58

ARG229 deletion ... 391

ARIMA ... 739

Arthroplasty ... 1567

Aspirin ingestion, before apheresis ... 1300

AS.TEC 204 ... 1104

ATP bioluminescence ... 1724

Autoantibodies
- blood transfusion-induced ... 5(E)
- formation after alloimmunization ... 67
- in teicoplanin-associated immune hemolytic anemia ... 73

Autoimmune hemolytic anemia ... 5(E), 67, 1287

Autoimmune neutropenia ... 1041

Autoimmunization, after transfusion ..... 5(E)
Autologous donation, preoperative 2S:1
Automated cell separator 758
Autotransfusion theory 2S:35

B

Babesia inactivation 731
Baboons 1004, 1505
BacT/ALERT 359, 1166, 1174
Bacterial contamination
  AABB standard and ..... 311(E)
  donor arm disinfectant 1238
  FDA and 450
  HPC product 907
  in PLT concentrates 330, 877
  RBCs 2S:4
  salvaged blood 2S:40
  wound blood 2S:45
Bacterial detection systems
  BacT/ALERT 1166
  glucose analysis ..... 1395(L)
  historical aspects 450
  pH analysis ..... 1261(L), 1395(L)
  for PLT concentrates ..... 337, 450, 461(L)
Bag manufacturing process, WPM from 1112
Band 3 anion channel 684, 838
Baxter Amicus plateletpheresis 1612
BC-PC preparations, automated 1052
B/D-- 1357
Bellovac ABAT device 1567
Bernard-Soulier-like syndrome 1588
Bernard-Soulier syndrome ..... 1790(L)
bGFG, in PLT gel 1013
Binding
  Annexin V 716
  cefotetan persistence on RBCs 849
  IgG 1186
Biochemical analysis, automated BC-PC preparations 1052
Biotin labeling 431
Blanchette scale 605
Bleeding
  Hb-based oxygen carriers for 1516
  intraoperative/postoperative 632
  massive, mortality and 1453
  outcome analysis 1135
  prophylactic platelet transfusion for ..... 1680(E), 1711
  severity measurement 605
Blindness, postoperative 2S:4
Blood administering practices, improving 1350
Blood-borne infections. *See also specific blood-borne infections*
  donor trends 1640
Blood centers, vCJD travel deferrals 645
Blood components. *See also specific blood components*
  posttransfusion survival 1025
  usage software 485
  WPM 967
Blood conservation ..... 2S:1, 631(E)
Blood flow, cerebral 414
Blood gas analysis, automated BC-PC preparations 1052
Blood groups. *See also specific blood groups*
  disease associations 1370
  genetics 1370
  specific antibodies ..... 5(E)
Blood loss. *See* Bleeding
Blood safety. *See* Safety
Blood substitutes ..... 1403(E)
Blood suppliers, hospital satisfaction with 1648
Blood supply
  adequacy 591
  losses, quantifying 1417
  viral attacks on ..... 467(E)
Blood transfusion. *See also* Allogeneic blood transfusion
  acute lung injury after 1468
  autoimmune hemolytic anemia risk and ..... 5(E), 67
  Fas/FasL expression after 158
  first, in Russia 1367
  GalT-KO pig RBCs 1004
  ICU guidelines 1450
  pseudothrombocytopenia 801
  rates in acute trauma 809
  recovery of PLT aggregation ability 891
  RhD variants 1282
  seroreversion after HCV infection 343
  survival/mortality after 386
Blood volume assessment, fluorescein-labeled HES 151
Bloody diarrhea prodrome, TTP-HUS risk 1384
Blow-molded bowl 917
BM infusion, noncryopreserved 907
BNP ..... 1533(L)
Bolton-Maggs scale 605
Bone marrow
  autologous, infusion of 907
  cell homing, after heart injury 239
Borna disease virus RNA ..... 1396(L)
Borrelia burgdorferi inactivation 1496
Bovine spongiform encephalopathy ..... 628(E), 675, 1475
Bradykinin 1361
Brazil blood donors 1579
Breast cancer 544
Bright field microscopy, WPM 959
Brown recluse spider envenomation hemolysis 1543
Buchanan scales 605
Buffy coats, holding before pooling 202
B19 virus 97, 1079, 1179

C

CABG surgery, adverse events 2S:4
CADP 764
Calcium, platelet storage and 49
Canada, societal unit cost of RBC transfusion 1479
CAP standards 450
Cardiac surgery
  adverse events 2S:4
  costs, leukoreduction and 30
  leukoreduction and 30, 489
  mortality, massive blood loss and 1453
  PLT transfusion ..... 1132(E)
  postoperative blindness 2S:4
Cardiovascular system, normovolemic hemodilution and 2S:26
Carriers, anti-D 1282
Causality, correlations and ..... 1132(E)
CD11b 722
CD3+ cells 1104
CD14+ cells 1104
CD34+ cells
  automated cell separator 758
  cell dose 253
  cord blood 262, 438
  large-volume leukapheresis 1593
  as marker for primitive progenitors in graft 785
  measurement in cord blood graft 547
  mobilization 104
  PBPC mobilization failure and 777, 1769
  yield predictions 526
CD62 exposure 49
CD177 polymorphisms 77
Ceftriaxone 1033
Cell salvage 1412, 2S:1, 40
Cell separation, wound blood 2S:45
Cellular therapy services
  assessment of 539
  production assistance ..... 1793(L)
Cell washer device, automated 900
CeNR 1047
Centrifugation, WPM and 1112
CEPI 764

Cerebral oxygenation, during blood donation 414
CFCs 785
CFU kinetics 104
CFU-megakaryocyte assay 555
Chemotherapy, prophylactic platelet transfusion ..... 1680(E), 1711
Children. *See* Pediatric patients
Chimerism ..... 1120(L), 1603
Chlamydia pneumoniae 1072
Chlorhexidine 1238
Cholesterol-to-phospholipid ratios 1231
Chronic lymphocytic leukemia 253
Circulating immature cells, prediction of CD34++ cell yields 526
Circulation, physiologic compensatory mechanisms 2:S26
Citrate phosphate dextrose, WPM 977
Citrobacter meningitis 1041
Clotting factor transfusion, alternatives 2S:1
CMV
  leukoreduction in open heart surgery 30
  photochemical treatment 1159
  screening 1059
  transfusion-associated ..... 1129(E)
CNS hemorrhage 1562
Coagulation 2S:26, 422
COBE Spectra device 119, 125, 1104
COBE Trima device 119, 125
Cold autoagglutinins ..... 5(E)
Collection. *See also specific collection methods*
  activity, in assessing cellular therapy services 539
  CD34++ 758
  CD14+ and CD3+ cells 1104
  PLT aggregation after transfusion 891
  WBC-reduced plasma 917
Colloid osmotic pressure, Hb-based oxygen carriers 1516
Column agglutination technology 187
Compatibility testing, without centrifuge 410
Composol 1204
Compound Adsorption Device 1732
Confidential unit exclusion option 651
Congenital disorders of secondary hemostasis 605
Contamination. *See also* Bacterial contamination
  in liquid nitrogen freezer ..... 942(L)
  PBPC products 1098
Cord blood
  automated cell washer device 900
  banking 111, 262
  CD133+ 1087
  CD34++ cells 438, 547
  infusion 907
  liquid and frozen storage 518
  variables 690
Cornea, persistent epithelial defects 1724
Correlations, causality and ..... 1132(E)
Corticosteroids 907
Cost-benefit ratio, of universal leukoreduction 10
Cost-effectiveness, of PCR for donor screening for malaria 217
Costs
  acute normovolemic hemodilution 2S:26
  open heart surgery, leukoreduction and 30
  PLT production ..... 461(L)
  RBC transfusion 1479
  unwashed wound blood retransfusion 2S:45
CR1 deletion 164
Creutzfeldt-Jacob disease, variant ..... 628(E)
  in donors 1243
  infectivity, protease treatment and 1700
  mammalian brain consumption by donors 667
  posttransfusion survival 1025
  precautionary principle and 1475
  screening of blood donors 675
  travel deferrals 645, 675
Cryoglobulinemia, cutaneous vasculitis and 145
Cryopreservation
  cord blood 518
  HPC 907
  long-term storage of RBCs 1306
  PBPCs 245, 785, 1098
C/T polymorphism 83
Culture bottles, plastic 359
Cultured cell products 539
Cutaneous vasculitis, cryoglobulinemia and 145
Cytochalasin B 865
Cytokines
  platelet reactions and ..... 1(E)
  polymorphisms in PLT concentrates 996
  storage-generated, in FNHTRs ..... 1(E)
Cytomate 900

D

D antigen
  partial high-grade 575
  race/ethnicity and 703
  variations 1663
Darboepoetin alfa 2S:15
DAT
  positive ..... 5(E), 67, 73
  RBC autoantibody with anti-E specificity 1287
  teicoplanin-associated immune hemolytic anemia 73
Databases
  ANH meta-analysis 632
  donor trends in blood-borne infections 1640
  survival/mortality data 386
  transfusion risks 2S:4
  TTP-HUS 1384
Dc-/D-- genotype 853
$DC^w(e)/D^-$ phenotype 1047
Decision-making, blood safety 1475
Deep venous thrombosis 586
Deferrals
  donor 1417
  travel, for vCJD 645, 675
Deformability, RBC 1231
Deglycerolization 990, 1656
Delayed hemolytic transfusion reactions ..... 5(E), 67
Delayed serologic transfusion reactions ..... 5(E)
Demographics
  transfusion-transmissible disease markers 1243
  WPM 977
des-Arg^9-BK
Desmopressin 2S:58
Dexamethasone 750
DFO 833
Diclofenac 1226
DIC microscopy, WPM 959
Diego blood system 684
Dimethylmethylene blue 716
Disinfectant, donor arm 1238
DMSO 785, 907
DNA profiling, for parentage verification 1513
DNA quantification test, B19V 97
DNA sequence analysis
  ABO ..... 1394(L)
  HAV tracing 1555
  hybrid novel *RHCE* gene 1047
  Kn^a/Kn^b identification 164
DNA typing
  for parentage testing 83
  resolution of misidentification 1750
Donath-Landsteiner antibody 1127
Donation. *See also* Donors
  cerebral near-infrared spectroscopy 414
  confidential unit exclusion option 651
  deep venous thrombosis complicating 586
  frequency, PLT function and 764
  hemochromatosis programs ..... 1535(L)
  iron loss 1427

repeated 1427, 1441
sickle cell trait, LD filters and 422
Donors
adverse effects ..... 135(L)
arm disinfectant 1238
blood-borne infection trends 1640
Chlamydia pneumoniae in PBMNCs 1072
CMV screening 1059
elemental iron for 1427
exclusion guidelines, transfusion-transmitted malaria and ..... 464(L)
female 591, 1427
first-time high school, reactions in ..... 463(L)
Hb AS 1293
HBsAg positive 1332
HBV DNA levels 1332
HCV risk factors 275, 1433
HCV seroprevalence 1344
HIV transmission window-period 929
incentives 597
iron supplementation for 1463
loss due to variant CJD travel deferral 645
lymphocyte-mediated anti-D hemolysis 1635
malaria screening 217
mammalian brain consumption 667
McLeod phenotype in random K:4 screening 1579
NAT screening of SARS-CoV 470
notification process 658
Polish, HCV core antigen in 1067
postleukapheresis cell counts 1104
predonation water ingestion and 924
quantifying losses 1417
reaction to notification process 658
recruitment 597
regular 1427, 1441
retention 924
RIBA-3-indeterminant results 349
symptoms 229
TRALI-associated 1774
transfusion-transmissible disease markers 1243
vCJD screening 675
WPM and 1112
Double-filtration plasmapheresis 1621
2,3-DPG, long-term stored RBCs 1306
Dressings, PLT gel 1013
Drug-dependent antibodies 1033
Drug-induced immune hemolytic anemia 73, 1033
Drugs. *See also specific drugs*
before cryopreserved BM and PBPC infusion 907
TTP-HUS risk 1384
D5S818 locus mutations 83
D typing, fluorescence cytometric 187

E

EACA 2S:58
E antigen 391
EGTA-AM, PLT storage 865
Electron microscopy, of WPM 959, 977
Elemental iron, for donors 1427
ELISA
anti-D affinity 399
CMV antigens 1059
HCVcAg 1067
HCV core antigen 1755
L-chain CDR3 mutants 173
L-chain mutants N-terminal mutants 173
Emergency RBC transfusions, pediatric 373
Endonuclease treatment 1079
Engraftment
HPC 253
lymphoid delayed ..... 946(L)
RBC 1603
stem cell 555
Epidemiology, WPM 977
Epitheliotrophic capacity, GF preparations 1724
Erythropoiesis 2S:15
Erythropoietic agents, for oncology patients 2S:15
Erythropoietic protoporphyria 1401
Erythropoietin 2S:15
Escherichia coli 1098
Ethics, vCJD screening 675
Ethnicity
ABO and Rh(D) phenotype 703
long-distance cord blood banking 111
Ethylene-oxide-induced pruritus ..... 1532(L)
Evidence-based medicine, ICU transfusion guidelines 1450
Exchange transfusion, microvascular response 1626
Extracorporeal photochemotherapy ..... 1531(L), 1532(L)

F

Family studies, hybrid novel *RHCE* gene 1047
Fas expression, after blood transfusion 158
Fas ligand expression, after blood transfusion 158
Fatigue, female blood donors 591
FDA
bacterial contamination and 450
confidential unit exclusion option 651
Febrile nonhemolytic transfusion reactions ..... 1(E), 16, 25
Female blood donors 591, 1427
Ferrous gluconate 1427
FFP
overusage ..... 1674(L)
physician requests ..... 1393(L)
posttransfusion ALI 1468
posttransfusion survival 1025
WPM 1112
Filgrastim 777
Filters
blockage, sickle cell trait blood donation 422
HB AS 1293
Hb sickle cell trait donations and 422
WBC retention 1271
WB-SP 1197
WPM reduction 959
FITC-HES blood volume assessment 151
Flow cytometry
CD34+ cells 104
CD133+ cord blood HPCs 1087
CD177 polymorphisms 77
ceftriaxone-induced thrombocytopenia 1033
GalT-KO pig RBCs 1004
holding buffy coats for pooling 202
McLeod phenotype in random K:4 screening 1579
neutrophil-specific antibodies 1041
platelet activation 125
WBC counting 1319
WPM 959
Flt3-L, cord blood CD34++ cells and 438
Fluorescence cytometric blood typing 187
FOCUS-PDCA model 1350
Forecasting, RBC transfusion demand 739
Fr^a antigen 684
Freeze-thaw wash recovery 547, 990, 1306, 1656
Functional capillary density 1626
FUT3 alleles, Lewis-null phenotypes ..... 1534(L)
FVII deficiency 1325

G

GalT-KO pig RBCs 1004
Gambro Trima Accel plateletpheresis 1612
Gamma irradiation, hemolysis and 1231
Gastrointestinal tract, vulnerability to ischemia 2:S26
GBV-C/HGV infection 268
G42C *NB1* polymorphism 77
G-CSF 104, 245, 544, 1755
Gel electrophoresis 601

Gene mapping 1370
Genetic recombination, novel Dc-/D-- genotype 853
Genetics/genomics 1370
Genotyping
  Knops 164
  McLeod phenotype in random K:4 screening 1579
  by minisequencing analysis ..... 943(L)
  in prenatal setting 1663
Gerbich blood group antigens 567
Glucose analysis, for bacterial detection screening ..... 1395(L)
GLU480 LYS 684
Glycerol 990, 1306, 1656
Glycophorin C, recombinant 567
Glycoprotein Iba 1487
Glycosylation, altered 1588
GPIb-IIa 1505
GPIb/IIa 1033
GPIX 1033
Granulocyte apheresis 750
Growth factors. *See also specific growth factors*
  in PLT gel for unhealing wounds 1013
  preparations, epitheliotrophic capacity 1724
Growth factors, in autologous PLT gel 1013
GVHD
  ABO incompatibility 1603
  allogeneic SCT 771
  ECP for ..... 1531(L)
  xenogeneic 282

H

HAART, HIV anemia treatment and 826
Haemonetics APC 215 990
Haemophilus influenzae 1127
Hamster window chamber model 1626
HAV ..... 1121(L), 1555
Hb
  content of RBC units, number of transfusions 485
  donor standards 591, 597
  hemolysis assessment 984
  normovolemic hemodilution endpoint 2S:26
  before RIC allo-SCT 501
  transfusion outcome 2S:4
Hb balance model 1019
Hb-based oxygen carriers ..... 1403(E), 1516
Hb S polymerization 1293
HBV
  DNA inactivation 476
  DNA levels in donors 1332
  donor prevalence trends 1640
  infected PBPCs harvests ..... 942(L)
  screening 1332
  as transfusion risk 2S:4
HCV
  detection 59
  donor prevalence trends 1640
  donor risk factors 275
  NAT screening 1706
  risk factors 1433
  seroconversion detection 59
  seroprevalence 1344
  seroreversion after infection 343
  suppression in hemophilia 790
  targeted lookback ..... 795(L)
  as transfusion risk 2S:4
HCVcAg test 1067
HCV core antigen 1067, 1755
Heart injury
  homing of marrow cells after 239
  ischemic 2:S26
Hemagglutination, L-chain CDR3 mutants 173
Hematocrit, transfusion outcome 2S:4
Hematopoietic progenitor cells
  bacterial contamination 907
  CD133+ cord blood 1087
  cryopreservation 907
  PBPC harvesting and 1762
  stem cell engraftment 555
Hematopoietic progenitor cell transplantation
  allogeneic stem 501, 771
  autologous 253, 544
  preparation 907
  pure red blood cell aplasia from ..... 946(L)
  RBC fragmentation after ..... 1791(L)
  TTP-HUS risk after 294, 1384
Hemochromatosis donor programs ..... 1535(L)
HemoCue method 984
Hemodynamics, during blood donation 414
Hemolysis
  ABO incompatibility 1603
  after chimeric RBC unit ..... 1120(L)
  brown recluse spider envenomation 1543
  detection of RBC membrane damage 716
  from D incompatibility 1635
  double-filtration plasmapheresis 1621
  needle-associated 373
  oxaliplatin-induced 838
  porphyrin photosensitizers 1186
  visual assessment 984
Hemolytic anemia, Donath-Landsteiner antibody-associated 1127
Hemolytic assay, GaIT-KO pig RBCs 1004
Hemolytic disease of newborn 1663
Hemolytic transfusion reactions 694, 1273
Hemophilia
  bleeding scales in 605
  B19 virus in 1179
  HCV suppression 790
  rFVIIa administration policies 1325
Hemorrhage
  CNS 1562
  Hb-based oxygen carriers for 1516
  ICU transfusion guidelines 1450
Hemostasis 2S:58, 1562
Hepatitis E, transfusion-transmitted 934
Hereditary hemochromatosis 597
High-separation core bowl 917
Hip arthroplasty 1567
Hip fracture, preoperative IV iron 1447
History
  blood group genetics 1370
  first blood transfusion in Russia 1367
HIV
  anemia treatment 826
  detection 59
  donor prevalence trends 1640
  long-term nonprogressors ..... 1397(L)
  transmission window-period 929
HLA antibodies
  in AAA 814
  long-distance cord blood banking 111
  multiple transfusions 1683
  TRALI and 1689
HLA-DQA1 amplification, for WBC counting 1314
Hospitals
  assessment of cellular therapy services 539
  costs for open heart surgery, leukoreduction and 30
  donor screening for malaria 217
  postoperative length of stay
    leukoreduction in open heart surgery 30
  satisfaction with blood suppliers 1648
HPA-5b 844
HPA mismatch, in PBPC transplantation 771
HPA-specific alloantibodies 1220
HTLV-I, removal by filtration 42
HTLV-II, removal by filtration 42
Human neutrophil antigen-2a 77, 581
Hypercoagulable states 586

Hyperkalemia 373
Hyperphosphatemia, after S/D-treated plasma exchange ..... 947(L)
Hypocalcemia symptoms, apheresis devices and 119
Hypotensive transfusion reactions 1361
Hypothermia, with acute normovolemic hemodilution 2S:26

I

IAT
positive ..... 5(E), 67
vs. slide Polybrene method 410
ICAM-1 1769
ICU
length of stay, leukoreduction and 30
transfusion guidelines 1450
Identification, patient
ABO mismatch 860
for HPC infusion 907
network computer-assisted transfusion-management system 364
parentage analysis ..... 1258(L)
IgA, prevention of anaphylactic transfusion reactions 509
IgG
binding, porphyrin photosensitizers and 1186
responsiveness against PLT transfusions 1572
IL-β polymorphisms, in PLT concentrates 996
Immune hemolysis, diclofenac-induced 1226
Immune hemolytic anemia
cefotetan persistence on RBCs 849
drug-induced 73, 1033
teicoplanin-associated 73
Immunization to D+ RBC, prevention of 1720
Immunoassays, HBV marker 1332
Immunoblot analysis, ceftriaxone-induced thrombocytopenia 1033
Immunocompetence, seroreversion after HCV infection 343
Immunocytochemistry, CD133+ cord blood HPCs 1087
Immunofluorescence staining, chlamydial antigen 1072
Immunohematology testing, fluorescence cytometric 187
Immunoprecipitation, ceftriaxone-induced thrombocytopenia 1033
Immunosuppression, as transfusion risk 2S:4
Inactivation, pathogen
B19 virus 1079
INACTINE PEN110 ..... 282, 476
PCT with amotosalen and UVA 877, 1159, 1496, 1732
porphyrin photosensitizers for 1186
West Nile virus 886
Indirect electrophoresis 173
Individual donation testing, WNV 1547, 1695
Infants
banked cord blood yield 262
cord blood variables and 690
HPA-5b alloimmune thrombocytopenia 844
neonatal alloimmune thrombocytopenia 1220
neutropenia and sepsis 1041
posttransfusion RBC recovery 1019
silent HAV infection ..... 1121(L)
transfused RBC kinetics 871
VLBW, posttransfusion RBC recovery 1019
Infection
PLT transfusion and 1143
postoperative, leukoreduction and 489
as transfusion risk 2S:4
Infectious disease. *See also specific infectious disease*
screening results, donor notification process 658
transmission, confidential unit exclusion option 651
Inflammatory markers 722
Injury Severity Score, blood transfusion rates 809
INTERCEPT 320
Interferon 790
Interleukin-8 722
InterSol 320
Intraoperative period, blood management 2S:1
Intrauterine transfusion
donor RBC deformability 1231
maternal ABO-mismatched blood 1357
Intravenous drug use
HCV infection risk in donors 275
Thai blood donors 1433
In-vitro model systems, Hb-based oxygen carriers 1516
In-vivo model systems, Hb-based oxygen carriers 1516
Iron
deficiency 2S:15
loss from blood donation 1427
overload, phlebotomy for 833
Iron therapy
female donors 597
hip fracture patients 1447
oncology patients 2S:15
oral preparations 2S:15
parenteral formulations 2S:15
2-unit RBC apheresis 1463
Isolation, CD133+ cord blood HPCs 1087
Isovolemic exchange transfusion 1626
ITP, bleeding scales 605
IVIG, parvovirus B19 neutralizing antibodies assay 1340

K

Kidd blood group 694
Knee arthroplasty 1567
Knops blood group 164

L

Laboratory workup, TRALI 1774
Lacey scale 605
Landefeld bleeding severity index 605
LDH release, in PCT platelets 320
Length of hospital stay 30, 489, 1143
Lenograstim 104, 544, 750
LeucoCOUNT method 1319
Leukapheresis
automated cell separator for 758
G-CSF and 1104
granulocyte 750
large-volume 229, 1593
Leukemia
acute 777, 833
chronic lymphocytic 253
prophylactic platelet transfusion ..... 1680(E), 1711
Leukocytes, as WPM 959
Leukopenia, TRALI 1689
Leukoreduction. *See also* Universal prestorage leukoreduction
hemolysis and 984
postoperative outcome and ..... 489, 1675(L)
prestorage 1361
selective *vs.* universal prestorage 16
whole-blood 1197
WPM and 959, 973, 1112
Lewis-null phenotypes, *FUT3* alleles ..... 1534(L)
Light microscopy, WPM 977
Linked -13SNP marker 83
Lipid peroxidation, gamma irradiation of RBCs and 1231
Liquid storage 245, 518
Liver transplantation 1635
Lookback study, TRALI 1683
L-selectin 1769
LTC-IC assay 438, 785
Lymphocyte products 539
Lymphoid engraftment, delayed ..... 946(L)
Lyophilization 1505

M

Mac-1 1769
Macroaggregates. *See* WPM
MAIGA 1041
Major histocompatibility complex 1572
Malaria
donor exclusion guidelines ..... 464(L)

PCR donor screening 217
Malignancy, cell salvage for 2S:40
Mammalian brain consumption, variant CJD transmission 667
Manual Polybrene method 410
Mass spectrometry, protein profiling 601
Mathematical modeling, cell salvage 1412
McLeod phenotype 1579
Mechanical ventilation, TRALI and 1468
Mederios scale 605
Mediastinitis 30
Medications. *See* Drugs; *specific drugs*
Methemoglobin 1231
Methylene blue-light treatment ..... 886, 948(L)
Mexico, HCV seroprevalence in donors 1344
Microarrays, protein 601
Microbial detection system 359
Microcirculation, physiologic compensatory mechanisms 2:S26
Microsampling 2S:1
Minipool NAT, failure to detect WNV 1695
Minisequencing analysis, ABO genotyping ..... 943(L)
Minority populations, long-distance cord blood banking 111
Misidentification
parentage analysis ..... 1258(L)
resolution by STR analysis 1750
Mismatched blood, ABO 860, 1357
Mixed lymphocyte reaction 1212
MN blood group system 173
MNC program 1104
MoAbs ..... 5(E), 399, 955
Mobilization
adhesion molecules and 1769
failure 777, 1769
G-CSF, splenic rupture after ..... 1260(L)
Molecular tracing, HAV 1555
Monocyte monolayer assay 197, 1273
Mortality
blood transfusion 386, 1025
leukoreduction in open heart surgery 30
massive blood loss and 1453
PLT transfusion and 1143
Mothers
banked cord blood yield 262
cord blood variables and 690
D$^-$, anti-D IgG prophylaxis 512
neutrophil-specific autoantibodies 1041
Multicomponent collection, platelet activation and 125
Multiple myeloma 544
Multiple transfusions ..... 5(E), 814
Murine transfusion model, CMV photochemical inactivation 1159
Mutations 83, 173
Mycoplasma species inactivation 286
Myeloablative therapy 253

N

NAT
combined HIV-1 and HCV 59, 91
HCV 275, 1706
individual-donation *vs.* minipool 1547
pooled, HIV transmission window-period 929
reduction of transfusion risk 2S:4
SARS-CoV 470
Nationwide Blood Collection and Utilization Survey 539
NB-1 gene 77
N box of *ABO* proximal promoter 1741
Near-infrared spectroscopy, during blood donation 414
Neonatal alloimmune thrombocytopenia 1220
Nervous system, normovolemic hemodilution and 2S:26
Neutropenia
autoimmune 1041
neonatal 1041
in TRALI 1689
Neutrophil concentrates, consecutive collection 750
Neutrophil number, in pregnancy 581
Neutrophil surface protein expression 77
Nondiscriminated reactive results 91
Nonendemic countries, transfusion-transmitted hepatitis E 934
Non-Hodgkin's lymphoma 253, 544, 777
Nonhospitalized patients, PCR malaria screening 217
Nonprogression, HIV long-term ..... 1397(L)
Normovolemic hemodilution, acute
cell salvage modeling and 1412
contraindications 2S:26
meta-analysis 632
selection criteria 2S:26
technique/outcomes 2S:1–2, 26
universal prestorage leukoreduction and 1361
N-terminal residues, L-chain mutants 173

O

O alleles 707
Obstetrics, cell salvage for 2S:40
Ocular surface defect treatment 1724
Oklahoma TTP-HUS registry 1149, 1384
Oncology patients
erythropoietin and iron therapy for 2S:15
prophylactic platelet transfusion ..... 1680(E), 1711
Open heart surgery, leukoreduction in 30
O platelet units, apheresis-derived 805
Optic nerve head, normovolemic hemodilution and 2S:26
OrbiSac device 1052
ORTHO HCVcAg test 1067
Orthopedic surgery 489
Osmotic fragility, long-term stored RBCs 1306
Outcomes
PLT transfusion ..... 1132(E), 1135, 1143
pregnancy, after TTP-HUS 1149
Outdating, PLT unit 1166
Oxaliplatin-induced hemolysis 838
Oxygen
hB-based carriers ..... 1403(E), 1516
microvascular distribution 1626
Oxygen saturation levels 1293

P

PAD, with acute normovolemic hemodilution 2S:26
Pall BDS pouch 337
Parentage testing
mismatches of allele size 83
prenatal, problems with ..... 134(L)
in refuting impersonations 1513
Partial DWI characterization 575
Particulate matter. *See* WPM
Parvovirus
detection in plasma 97
in hemophilia A 1179
susceptibility to low pH 1079
Parvovirus B19 neutralizing antibodies assay 1340
Passenger lymphocyte syndrome ..... 1259(L)
Pathogen reduction technology ..... 286, 731. *See also* Inactivation, pathogen; Photochemical treatment
Patient care, HPC infusion 907
p blood group phenotype, in China ..... 136(L)
PBMNCs, *Chlamydia pneumoniae in* 1072
PBPCs
donors, G-CSF-treated ..... 1260(L), 1755
efficacy of large-volume leukapheresis 1593
G-CSF-mobilized, extended storage 245
HBV infected harvests ..... 942(L)
infusions
allogeneic ..... 1259(L), 1603
autologous ..... 907, 1680(E), 1711
microbial contamination 1098
mobilization failure 777, 1769
mobilization with G-CSF, kinetics of 104
noncryopreserved, infusion of 907

retention of cellular properties after liquid storage and cryopreservation ... 245
timing of harvest ... 1762
PCA ... 187
PCA-96 ... 187
PCR
ABO sequence analysis ... 1394(L)
detection of HBV DNA inactivation ... 476
donor screening for malaria, cost-effectiveness of ... 217
D5S818 alleles ... 83
evaluation of HTLV-I removal by filtration ... 42
HAV tracing ... 1555
HBV DNA ... 1332
HLA-DQA1 amplification for WBC counting ... 1314
McLeod phenotype in random K:4 screening ... 1579
Parvoviridae susceptibility to low pH ... 1079
posttransfusion Kidd blood group typing ... 694
real-time B19V DNA ... 97
WNV-DNA ... 1695
WNV MB-light inactivation ... 886
PDGF, in PLT gels ... 945(L)
Pediatric patients. *See also* Infants
aprotinin in ... 2S:58
emergency RBC transfusions, hyperkalemia and ... 373
leukapheresis, large-volume ... 229
posttransfusion RBC recovery ... 1019
rHuEPO for PABD program ... 1122(L)
PEN110 treatment ... 282, 476
Perioperative period, PLT transfusion and ... 1143
PFA-100, in plateletpheresis donors ... 764
Phages display technology ... 5(E)
pH analysis
for bacterial detection ... 1261(L), 1395(L)
leukoreduced PLT concentrates ... 330
Phase change material ... 210
pH-based inactivation, B19 virus ... 1079
Phlebotomy, for iron overload ... 833
Phosphatidylserine ... 49
Photochemical treatment
with amotosalen and UVA ... 877, 1159, 1496, 1732
platelet functional characteristics and ... 313, 320
PLT concentrate ... 313, 877, 1496
safety improvement and ... 1129(E)
West Nile virus inactivation ... 886
Photodynamic treatment
membrane damage, RBC marker sensitivity and ... 716
porphyrin ... 1186
Photosensitizers, for RBC sterilization ... 1186
Phylogenetic analysis
HEV ... 934
HIV ... 929
Physicians
FFP requests ... 1393(L)
TM fellowship ... 1252
Placental transfer, maternal neutrophil-specific autoantibodies ... 1041
Plasma collection, WBC-reduced ... 917
Plasma exchange
S/D-treated ... 947(L)
TMA subpopulations ... 146
Plasmapheresis
double-filtration ... 1621
perioperative ... 2S:54
Plasma pooling
flow cytometric WBC counting ... 1319
holding buffy coats for ... 202
testing ... 97
Plasma volume, FITC-HES estimates ... 151
Plasmodium inactivation ... 731
Platelet activation ... 125
Platelet additive solution ... 320
Platelet aggregation
after storage ... 891
apheresis devices and ... 125
aspirin and ... 1300
Bernard-Soulier-like syndrome ... 1588
lyophilization and ... 1505
photochemical treatment and ... 313
Platelet concentrates
automated buffy-coat pooled ... 1052
bacterial contamination detection system ... 337
growth factor preparations from ... 1724
leukoreduced ... 10
efficacy standard for ... 36
for open heart surgery ... 30
prestorage ... 1(E)
storage of ... 330
photochemical treatment ... 313, 877, 1496
posttransfusion clearance ... 1487
posttransfusion survival ... 1025
preparation, evaluation criteria for ... 36
production costs ... 461(L)
quality assessment ... 1052
residual WBCs, counting method ... 1314
storage, aggregation and ... 891
Platelet count, before and after PC transfusion ... 891
Platelet culture, automated ... 1166, 1174
Platelet disorders, rFVIIa administration policies ... 1325
Platelet engraftment ... 771
Platelet gels
PDGF and TGF-b in ... 945(L)
for unhealing wounds ... 1013
Platelet immunity, in inbred mice ... 1572
Platelet-labeling studies ... 131
Platelet markers, posttransfusion clearance ... 1487
Plateletpheresis
aspirin ingestion before ... 1300
donors, PFA-100 in ... 764
perioperative ... 2S:54
PLT activation during ... 125
single-needle ... 1612
yield calculation ... 2S:54
yield per pheresis cycle ... 2S:54
Platelet-plasma preparations ... 49
Platelet pools, from whole blood ... 461(L)
Platelet-rich plasma, viability assessment ... 131
Platelets
apheresis, with anti-IgA ... 382
bacterial contaminants, plastic culture bottles and ... 359
bacterial detection systems ... 1166, 1174
flow cytometric WBC counting ... 1319
photochemically treated ... 313, 320
prestorage pooled ... 1212
random-donor, bacterial contamination detection system ... 337
recovery and life span after PCT ... 1732
responsiveness during storage ... 49
survival ... 36
swirling ... 627
12-day storage ... 1204
viability assessment ... 131, 865
WB-SP filters and ... 1197
whole-blood-derived leukoreduced, prestorage pooled ... 1212
as WPM ... 959, 1112
Platelet storage lesions ... 1300
Platelet storage systems, evaluation criteria ... 36
Platelet transfusion
allogeneic ... 1143
autoantibody formation after ... 5(E)
bacterial contamination and ... 311(E), 450
during CABS ... 1143
cardiac surgery ... 1132(E)
febrile nonhemolytic transfusion reactions and ... 1(E)
infant anti-D ... 747
low-dose prophylactic ... 1680(E), 1711
posttransfusion reactions, effect of UPL on ... 16
risks ... 2S:4
triggers ... 1135

Platelet yield, COBE Trima *vs.* COBE Spectra device 119
PMN chemotaxis 722
PMN concentrates, consecutive collection 750
PMN priming, by RBC supernatant 722
pO_2 1627
Poland, HCV NAT screening 1067, 1706
Polycythemia, FITC-HES blood volume assessment 151
Polymorphisms
  Kn^a/Kn^b 164
  in PLT concentrates 996
  single nucleotide 77
Porphyrins 1186
Postoperative autologous transfusion 1567
Postoperative infections, leukoreduction and ..... 489, 1675(L)
Posttransfusion
  CMV ..... 1129(E)
  purpura ..... 5(E)
  recovery, allogeneic RBCs in infant 871
  survival 1025
Potassium leakage 716, 1186
Precautionary policies, vCJD and 1475
Prediction, CD34++ yield 526
Pregnancy
  HNA-2a expression in 581
  neutrophil number in 581
  outcomes after TTP-HUS recovery 1149
  TTP-HUS risk 1384
Premature labor, HNA-2a expression in 581
Preoperative planning 2S:1
Processing, blood 539
Procleix HIV-1 and HCV assay 59, 91
Progenitor assays, cord blood 518
Protease-resistant prion protein 1700
Protein profiling 601
Proteomics 601
Protoporphyria, erythropoietic 1401
Protozoan parasite inactivation 731
Proximal promoter, *ABO* gene transcription and 1741
PRP-derived PLTs, BacT/ALERT 1174
Pruritus, ethylene-oxide-induced ..... 1532(L)
PRV-1 gene 77
P-selectin
  expression in PCT-PLTs 313, 320
  in fresh and lyophilized PLTs 1505
  multicomponent PLT collection and 125
  posttransfusion clearance of PCs 1487
Pseudothrombocytopenia 801
Psoralens, murine CMV inactivation 1159
Pulmonary system, normovolemic hemodilution and 2S:26
Pure red cell aplasia ..... 946(L), 1603

R

Race 703
Radiolabeling, of PLTs 36, 131
RBC agglutination
  ceftriaxone-induced thrombocytopenia 1033
  porphyrin photosensitizers 1186
RBC antibodies
  alloantibodies 187, 1273
  autoantibody mimicking anti-E 1287
  diclofenac-induced 1226
RBC apheresis, 2-unit 1463
RBC engraftment 1603
RBC exchange 1720
RBC fragmentation, after HPCT for TTP-HUS ..... 1791(L)
RBC marker sensitivity, photodynamic membrane damage and 716
RBC membrane epitope, oxaliplatin-induced hemolysis and 838
RBCs
  allogeneic , societal unit cost 1479
  buffy-coat-reduced 1319
  cefotetan persistence 849
  frozen 990, 1306
  iceless blood transport containers 210
  leukoreduced 1656
  leukoreduction before storage ..... 1(E)
  posttransfusion recovery, in VLBW infants 1019
  Tr polyagglutination 1588
  viability assessment 131
RBC supernatant, PMN priming 722
RBC transfusions
  adverse impact 722
  after RIC and allotransplant 501
  autoimmune hemolytic anemia risk and ..... 5(E), 67
  demand forecasting 739
  Hb content of units 485
  ICU guidelines 1450
  leukoreduced 10, 30
  pediatric emergency, hyperkalemia and 373
  reactions, leukoreduction effect on 16, 25
  societal unit cost 1479
RBC units
  chimeric, hemolysis after ..... 1120(L)
  PEN110 inactivation of HBV in 476
  posttransfusion kinetics 871
  transfusion risks 2S:4
  visual hemolysis assessment 984
  WPM in ..... 956(E), 977
RBC volume
  circulating, measurement of 431
  FITC-HES PV estimates 151
Recipients
  multiple HLA antibodies 1683
  posttransfusion survival 1025
  WPM risk 1112
Recruitment, donor 597
Red light-emitting diode 716
Reduced intensity chemotherapy-based conditioning 501
Reinfusion, of drain blood 1567
Remicade-induced serum sickness 955
Reporter gene transduction, cord blood CD34++ cells and 438
Respiratory medication use, PLT transfusion and 1143
Retina, normovolemic hemodilution and 2S:26
Retransfusion, unwashed wound blood 2S:45
Retrovirus Epidemiology Donor Study 667, 1243
RFLP analysis, novel Dc-/D-- genotype 853
rFVIIa
  administration policies 1325
  appropriate usage ..... 1544(E)
  for Bernard-Soulier syndrome ..... 1790(L)
  for CNS hemorrhage 1562
RhAG 1663
RhBG 1663
Rh blood group
  genetics 1370
  incompatibility 1635
  infant anti-D from PLT transfusion 747
  prevention of immunization 1720
  race/ethnicity and 703
RHCE gene
  amplification 407
  hybrid novel 1047
  variants 1283, 1663
RhCG 1663
RhD variants 1282
Rhesus antigen E^W 407
Rh gene complexes, novel CcEe-deleted 853
Rh hemolytic disease 1231
RhIg 1720
RH locus 853
rHuEPO
  with IV iron for hip fracture patients 1447
  for pediatric PABD program ..... 1122(L)
Ribaviarin, HCV suppression in hemophilia 790
Riboflavin 877
Risk
  autoimmune hemolytic anemia ..... 5(E), 67

transfusion 2S:4
WPM 1112
RT-PCR 391, 1072, 1087, 1555
Russia, first blood transfusion in 1367

S

Safety
bleeding outcome analysis 1135
decision-making 1475
Hb-based oxygen carriers 1516
improving ..... 1129(E), 1350, 1377
methylene-blue-photoinactivated plasma ..... 948(L)
NAT screening of SARS-CoV 470
rFVIIa administration policies 1325
transfusion, improving 1377
WPM and 967
Salvaged blood 2S:35
SARS ..... 467(E), 470
SCF, cord blood CD34++ cells and 438
SDS-PAGE, CMV antigens 1059
Selective leukoreduction 16
Sensitivity
of Procleix HIV-1 and HCV assay 59
of vCJD screening 675
Sepsis
Hb-based oxygen carriers for 1516
neonatal 1041
Seroconversion, HIV window-period 929
Serology
HAV tracing 1555
Knops phenotypes 164
McLeod phenotype in random K:4 screening 1579
Seroreversion, after HCV 343
Serum sickness, monoclonal antibody-stimulated 955
SERVQUAL satisfaction survey, hospital satisfaction with blood suppliers 1648
Sex-specific prevalence, blood-borne infections in donors 1640
Sexual partners, Thai blood donors 1433
Short tandem repeats ..... 83, 134(L), 1750
Siblings
McLeod phenotype in random K:4 screening 1579
parentage impersonations 1513
Sickle cell disease, autoimmune hemolytic anemia of ..... 5(E)
Sickle cell trait 422, 1293
Single-donor platelets, COBE Trima *vs.* COBE Spectra device 119
Single nucleotide polymorphisms, high-frequency 77
Slide Polybrene method 410
Software
blood component usage 485
evaluation of HSC bowl 917
Southern blot analysis 391, 1079, 1579
Specificity
anti-E, in RBC autoantibody 1287
HCVcAg test 1067
Procleix HIV-1 and HCV assay 59
real-time B19V DNA testing 97
vCJD screening 675
Spectrophotometry, hemolysis 984
Spinal surgery, rHuEPO for pediatric PABD program ..... 1122(L)
Splanchnic perfusion 2:S26
Spleen T cells 158
Splenic rupture, after G-CSF mobilization ..... 1260(L)
Sri Lanka, Lewis-null phenotypes ..... 1534(L)
Staphylococcus epidermidis, in PBPC products 1098
Stem cell engraftment 555
Stem cell transplantation
ABO-mismatched, pure red blood cell aplasia from ..... 946(L)
allogeneic 501, 771
autologous 544
Storage
contamination during ..... 942(L)
cord blood 518
cytokines and polymorphisms in PLT concentrates 996
extended, of G-CSF-mobilized PBPCs 245
hemolysis and 984
holding buffy coats for pooling 202
leukoreduced PLT concentrates 330
long-term, frozen RBCs 1306
pediatric emergency RBC transfusions, hyperkalemia and 373
platelet responsiveness and 49
PLT 865
PLT aggregation decrease 891
prestorage pooled WBD-PCs 1212
RBC, microvascular perfusion and 1626
12-day PLT 1204
Stroke, PLT transfusion and 1143
Surgery. *See also* Cardiac surgery
orthopedic 489
rFVIIa administration policies 1325
Surveillance, WPM and 967
Survival, posttransfusion 386, 871, 1025
Syphilis, donor prevalence trends 1640
Sysmex SE9000 1762

T

T-bag S59 Reduction Device 313
Teicoplanin-associated immune hemolytic anemia 73
Temperature
cord blood storage 518
iceless blood transport containers 210
long-term storage frozen RBCs 1306
Terumo Teruflex XT612 platelet container ..... 1395(L)
TGF-b, in PLT gels ..... 945(L)
Thai donors, HCV risk factors 1433
Thalassemia ..... 5(E)
Threatened abortion 581
Thrombin generation, platelet storage and 49
Thrombocytopenia
alloimmune 844
ceftriaxone-induced 1033
posttransfusion ALI 1468
Thrombocytopenic purpura-hemolytic uremic syndrome. *See* TTP-HUS
Thrombopoietin, PLT storage and 865
Thrombopoietin peptide agonist 438
Thrombotic microangiopathy 146
Thromboxane A2 1505
Thrombus formation, platelet storage and 49
Time-series methods, in forecasting RBC transfusion demand 739
Time to neutrophil engraftment 253
Tissue blood flow, Hb-based oxygen carriers 1516
Tissue oxygenation, Hb-based oxygen carriers 1516
TMB method 984
TM fellowship 1252
TNF polymorphisms, in PLT concentrates 96
Total hip arthroplasty 1567
Total knee arthroplasty 1567
Total nucleated cells, in cord blood 262, 547, 690
Tracers, for blood volume assessment 151
TRALI
BNP evaluation of ..... 1533(L)
definition of 1774
FFP usage ..... 1674(L)
incidence 1774
lookback study 1683
in mechanically ventilated patients 1468
risk factors 1774
symptoms 1774
Transcriptional regulation, *ABO* gene 1741
Transcription-mediated amplification, WNV-DNA 1695
Transfused volume, unwashed wound blood retransfusion 2S:45
Transfusion-management system, network computer-assisted 364
Transfusion medicine
physician training 1252
policy, anti-A/A,B titers in group O SDP 805
rFVIIa administration policies 1325

Transfusion reactions
- acute ... 1(E)
- allergic ... 16, 25
- anti-IgA ... 382
- delayed hemolytic ... 5(E), 67
- delayed serologic ... 5(E)
- effect of leukoreduction on ... 25
- febrile nonhemolytic ... 1(E), 16, 25
- hypotensive ... 1361
- IgA anaphylactic ... 509
- universal WBC reduction and ... 10
- unwashed wound blood ... 2S:45
- WPM and ... 967

Transplant-related mortality ... 1603
Transport, blood ... 210, 518
Transport containers, iceless ... 210
Trasylol ... 1143
Trauma
- blood transfusion rates ... 809
- rFVIIa administration policies ... 1325

Travel deferrals, vCJD ... 645, 675
Treponema pallidum inactivation ... 1496
Tr polyagglutination ... 1588
Trypanosoma cruzi inactivation ... 731
T-Sol ... 320
TTP-HUS
- after allogeneic HPC transplantation ... 294
- Oklahoma registry ... 1149, 1384
- RBC fragmentation in ... 1791(L)

Typing
- fluorescence cytometric ... 187
- posttransfusion, Kidd blood group ... 694

U

Umbilical cord blood. *See* Cord blood
Universal prestorage leukoreduction
- COBE Trima *vs.* COBE Spectra device ... 119
- cost-benefit ratio ... 10
- FNHTR and ... 10
- HTLV-I removal ... 42
- transfusion reactions and ... 1(E), 16, 25, 1361
- *vs.* selective leukoreduction ... 16

UVA light treatment, with amotosalen ... 877, 1159, 1496, 1732

V

Vasopressors ... 1143
Vasovagal reactions ... 591
vCJD. *See* Creutzfeldt-Jacob disease, variant
VEGF ... 438, 1013
Venous access ... 907
Viruses. *See also specific viruses*
- attacks on blood supply ... 467(E)
- photochemical inactivation in PLT concentrates ... 877

Viruses, transfusion-transmitted
- B19 ... 1179
- HAV ... 1121(L), 1555
- hepatitis E ... 934
- methylene blue-light treatment ... 886
- WNV ... 1547

Viscosity, Hb-based oxygen carrier ... 1516
Vitamin K ... 1325
VIT-VIV correlation analysis ... 1487
VLA-4 ... 1769
VNTR
- mutations ... 83
- prenatal parentage analyses ... 134(L)

VWD ... 605
VWF antigen, in plateletpheresis donors ... 764

W

Wafer SRD ... 313
Warm autoantibodies ... 5(E), 67
Washing, of salvaged blood ... 2S:35, 45
Wastage, of blood ... 1479
Water ingestion, predonation ... 924
WBC concentrates, residual WBC count ... 1257(L)
WBC count
- COBE Trima *vs.* COBE Spectra device ... 119
- flow cytometric ... 1319
- residual, in PLT concentrate ... 1314
- TRALI ... 1689

Weight, maternal ... 512
Western blot analysis, CMV antigens ... 1059
West Nile virus
- individual-donation NAT ... 1547, 1695
- methylene blue-light treatment ... 886
- minipool NAT failure ... 1695

Whole-blood-derived leukoreduced PLTs ... 1212
Whole-blood donation
- adverse effects ... 135(L)
- DVT after ... 586
- leukoreduction ... 1197

Window period
- HCV RNA ... 1706
- HIV ... 929

Wound blood reinfusion ... 2S:45, 1567
Wound healing, PLT gel for ... 1013
WPM
- in additive solution-1 ... 977
- ad hoc industry review ... 1112
- adverse events ... 973
- frequency/characteristics ... 977
- PLTs and leukocytes as ... 959
- in RBC components ... 956(E)
- risk ... 967

X

Xenotransplantation animal model ... 555

Y

Yield
- banked cord blood ... 262
- CD34++ ... 526
- CD14+ and CD3+ ... 1104
- COBE Trima *vs.* COBE Spectra device ... 119
- large-volume leukapheresis ... 229, 1593